Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab and Dupilumab in Asthma
NCT03387852Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2018
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of itepekimab in asthma (4 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Loss of Asthma Control at 12 weeks. Started Mar 2018; status: completed.
02
Drugs
itepekimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03387852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387852.